Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.15
+0.27 (5.53%)
Nov 26, 2025, 4:00 PM EST - Market closed
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $400.00K in the twelve months ending September 30, 2025.
Revenue (ttm)
$400.00K
Revenue Growth
n/a
P/S Ratio
697.71
Revenue / Employee
$2,941
Employees
136
Market Cap
279.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
| Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
| Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
| Dec 31, 2020 | 10.00M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABEO News
- 15 days ago - Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead - Seeking Alpha
- 15 days ago - Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Here's Why Abeona Therapeutics Popped Higher Today - The Motley Fool
- 15 days ago - Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 20 days ago - Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation - GlobeNewsWire
- 24 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel) - GlobeNewsWire
- 5 weeks ago - Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs - GlobeNewsWire